We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04498325
Recruitment Status : Withdrawn (Principal investigator is leaving the institution.)
First Posted : August 4, 2020
Last Update Posted : August 5, 2021
NeoImmune Tech
Information provided by (Responsible Party):
Washington University School of Medicine

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : April 30, 2022
Estimated Study Completion Date : April 30, 2022